Skip to main content

Advertisement

Table 4 Published studies of adjuvant chemotherapy in early stage ovarian cancer

From: Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group

Study Type of study Treatment Pts 5y RFS 5y OS
Young, 19906 Prospective, randomized Melphalan 32P 68 73 80% 80% 81% 78%
Vergote, 19921 Prospective, randomized Cisplatin 32P 171 169 81% 83% 75% 81%
Bolis, 19955 Prospective, randomized Cisplatin 32P 82 79 85% 65% 81% 79%
Young, 199920 Prospective, randomized Cyclo/Cisplatin 32P 107 98 77% 66% 84% 76%
Trope, 20007 Prospective, randomized Carboplatin No treatment 81 81 70% 71% 86% 85%
Trimbos, 20038 Prospective, randomized Platinum-based No treatment 224 224 76%* 68% 85% 78%
ICON1, 20039 Prospective, randomized Platinum-based No treatment 241 236 73%@ 62% 79%# 70%
Present study Retrospective, nonrandomized Paclitaxel/Carboplatin 69 79% 87%
  1. RFS: relapse-free survival; OS: overall survival; *: p = 0.02; @: p = 0.01; #: p = 0.03